基于双功能纳米酶的"丰富检测"电化学发光生物传感器,用于定量检测具有PD-L1的外体
Yaqi Qin1, Yuling Li1, Bo Shen2
1Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, P.R. China.
Analytical chemistry
|March 2, 2026
概括
这项研究引入了一种新型的电化学发光 (ECL) 生物传感器,用于检测编程死亡连接物1-阳性 (PD-L1+) 外体. 这项创新有助于非小细胞肺癌 (NSCLC) 的诊断和预测免疫检查点抑制剂 (ICI) 反应.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 癌症的诊断 癌症的诊断
背景情况:
- 编程死亡干1-阳性 (PD-L1+) 外体是非小细胞肺癌 (NSCLC) 查和预测免疫检查点抑制剂 (ICI) 反应的关键生物标志物.
- 在PD-L1+外体检测当前的挑战包括难以从复杂的生物样本中分离,并实现高分析灵敏度.
- 为了改善NSCLC患者管理,需要敏感和特定的检测方法.
研究的目的:
- 开发一个创新的创新.
- 丰富检测 - 检测丰富的检测
- 电化学发光 (ECL) 生物传感器用于定量检测PD-L1+外体.
- 利用模仿酶的磁性半孔- (MMS@Pd) 双功能纳米酶 (BFNs) 来增强外体体捕获和信号放大.
- 为NSCLC诊断和治疗监测提供一个敏感和可靠的工具.
主要方法:
- 合成MMS@Pd BFNs使用接口协同组装的减少方法,利用Fe3O4进行磁性收获和中孔二氧化用于结合.
- 演示合成的MMS@Pd BFNs的磁性和过氧化酶类活动.
- 构建一个ECL生物传感器,结合MMS@Pd BFNs,用于同时丰富和检测PD-L1+外体.
主要成果:
- 开发的ECL生物传感器成功丰富并检测PD-L1+外体.
- 生物传感器表现出从1×10^3到1×10^9颗粒子/毫升的广泛检测范围.
- 达到了69.66颗粒/毫升的低检测极限,表明高灵敏度.
- 生物传感器在分析临床样本方面表现出色.
结论:
- 集成的双功能ECL生物传感器为PD-L1+外体检测提供了一个灵敏和高效的平台.
- 这一创新策略对NSCLC的诊断和治疗具有重大潜力.
- 开发的生物传感器为以外体分析为指导的个性化癌症治疗提供了一个有前途的工具.
更多相关视频
09:16Rapid Fluorescence-based Characterization of Single Extracellular Vesicles in Human Blood with Nanoparticle-tracking Analysis
Published on: January 7, 2019
10.4K
09:30Using Nanoplasmon-Enhanced Scattering and Low-Magnification Microscope Imaging to Quantify Tumor-Derived Exosomes
Published on: May 24, 2019
7.9K
相关概念视频
Overview of Exosomes
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Enzyme-Linked Immunosorbent Assay
In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or quantified.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or quantified.
